2025-06-26 オックスフォード大学
Close up of injection Credit: Shutterstock
<関連情報>
- https://www.ox.ac.uk/news/2025-06-26-single-shot-malaria-vaccine-delivery-system-could-transform-global-immunisation
- https://www.science.org/doi/10.1126/scitranslmed.adw2256
日常的な注射に適合するコアシェルマイクロカプセルにより、1回の注射でマラリアに対するプライム/ブースト免疫化が可能になる Core-shell microcapsules compatible with routine injection enable prime/boost immunization against malaria with a single shot
Romain Guyon, Sören Reinke, Adam Truby, Lee Sims
Science Translational Medicine Published:25 Jun 2025
DOI:https://doi.org/10.1126/scitranslmed.adw2256
Editor’s summary
A major challenge for vaccine deployment is the need for booster immunizations. Here, Guyon et al. developed an approach to addressing this concern. The authors developed a chip-based strategy to load microcapsules with the R21 malaria vaccine. The microcapsules broke down over time in vivo, releasing the booster dose of vaccine at a time similar to when a boost would be administered. When given to mice along with the priming dose of R21 through a single injection, the microcapsules achieved nearly the same magnitude of antibody response as a standard prime/boost approach, offering high efficacy against malaria challenge. Thus, these microparticles, which also maintained immunogenicity with storage, represent an important advance for global immunization campaigns. —Courtney Malo
Abstract
Inadequate booster uptake threatens the success of immunization campaigns as seen with the recently rolled-out R21 malaria vaccine. The ability to administer both prime and boost immunizations with a single injection would therefore save lives and alleviate health care burdens. We present a platform for delayed delivery of the booster dose that is scalable with existing technology, easily injectable, and protective against malaria in vivo. Using chip-based microfluidics, we encapsulated the R21 malaria vaccine in polymer microcapsules that release their content weeks to months postinjection. Coinjecting microcapsules with the priming dose of the R21 vaccine elicited strong antibody responses in a mouse model and provided 85% of the protection of a standard prime/boost schedule. If confirmed in humans, these results would pave the way for rapid deployment of single-shot prime/boost vaccination, an urgently needed global health intervention.
